Skip to main content

Home/ Health affairs/ Group items tagged Gender-incongruence-treatment

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

NHS England 's Decision on Puberty Suppressing Hormones - 0 views

www.pharmacy.biz/...avigate-new-regulatory-hurdles

Puberty-suppressing-hormones-NHS-England Gender-incongruence-NHS-England NHS-England-review Gender-incongruence-treatment

shared by pharmacybiz on 23 Mar 24 - No Cached
  • pharmacybiz on 23 Mar 24
     
    NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:
1 - 1 of 1
Showing 20▼ items per page